RxDoctor Payments Data

Laura Paige, APRN

Primary Care · Clermont, FLNPI 1669132445

Payments from drug & device makers

$791in general payments, 2019–2025

Across 32 payments — averaging $24.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$380
  • GSK$175
  • Exact Sciences$41
  • Lilly USA, LLC$40
  • Bayer$30
  • Pfizer$24
  • plus $102 from 6 others

What the payments were for

  • Food & beverage$791100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$791 in reported general payments places this provider in the 65th percentile of 725 primary care providers in Florida.

See all primary care providers in Florida

Medicare billing

Part B allowed, 2024
$4,697
Medicare patients
60
Services billed
279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin43$43,023
MounjaroTirzepatide30$36,915
OzempicSemaglutide31$29,951
FarxigaDapagliflozin Propanediol27$25,304
EliquisApixaban16$22,182
TrulicityDulaglutide21$20,355
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$16,566
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$14,398
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,280
Albuterol Sulfate HfaAlbuterol Sulfate55$1,865
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,543
Gabapentin67$858
Atorvastatin Calcium72$692
Pregabalin11$474
Trazodone Hcl55$469

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$40$57,27051 claims
AstraZenecaFarxiga, Breztri Aerosphere$15$41,86952 claims
Novo NordiskOzempic$18$29,95131 claims
PfizerEliquis$24$22,18216 claims
GSKTrelegy Ellipta$175$14,39821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 725 primary care providers in Florida.

Other primary care in Clermont

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →